In the Group B treated with Peg IFNα plus Ribavirin and Silybin complex, we observed a significant improve (p < 0.05) of WAI at 12 months and at follow-up; a significant decrease of absenteeism (p < 0.05) at 12 months and at follow-up; a significant reduction of depression at 12 month and at follow-up, and a reduction of anxiety at 6, 12 months and at follow-up. The gene discussed is IFNA2; the disease is depressive disorder.